4.5
Malattia polmonare ostruttiva cronica I: Introduzione
La broncopneumopatia cronica ostruttiva è un disturbo respiratorio comune, prevenibile e curabile, caratterizzato da sintomi persistenti e da una prog…
La broncopneumopatia cronica ostruttiva, o BPCO, è un disturbo polmonare comune, prevenibile e curabile. Presenta sintomi respiratori persistenti e limitazioni del flusso d'aria, solitamente causate da esposizione a lungo termine a particelle o gas dannosi che portano a infiammazione cronica e danni polmoniari.
Nella BPCO, l'infiammazione cronica provoca cambiamenti duraturi nelle vie aeree e nelle sacche aeree. Questi cambiamenti possono includere enfisema, che colpisce le sacche aeree, e, in alcune persone, segni di bronchite cronica, come tosse e muco in eccesso.
I principali fattori di rischio includono il fumo di tabacco, l'esposizione occupazionale a polvere e fumi chimici, e l'inquinamento dell'aria interna dovuto all'uso di combustibile a biomassa per cucinare e riscaldare in abitazioni mal ventilate.
Altri rischi includono infezioni come la tubercolosi o infezioni respiratorie infantili ripetute come la polmonite.
Un fattore genetico chiave è la carenza di alfa-1 antitripsina, una condizione che compromette la capacità dei polmoni di contrastare gli enzimi proteolitici, portando a danni tessuti accelerati e a un aumento del rischio di BPCO ad insorgenza precoce.
View the full transcript and gain access to JoVE Core videos
Q1: What causes chronic obstructive pulmonary disease?
COPD results from long-term exposure to harmful particles or gases causing chronic inflammation and lung damage. Major risk factors include tobacco smoke, occupational dust and chemical fumes, indoor air pollution from biomass fuels, and infections like tuberculosis or repeated childhood pneumonia. Genetic factors, particularly alpha-1 antitrypsin deficiency, also increase susceptibility to early-onset COPD.
Q2: How does chronic inflammation damage the lungs in COPD?
Chronic inflammation causes lasting structural changes in airways and air sacs. These changes include emphysema, which destroys alveolar walls and reduces elastic recoil, and chronic bronchitis, characterized by airway inflammation and excess mucus production. Together, these pathological processes limit airflow and impair gas exchange.
Q3: What is the difference between emphysema and chronic bronchitis in COPD?
Emphysema involves destruction of alveolar walls and loss of elastic recoil in air sacs. Chronic bronchitis is defined by chronic cough and sputum production due to airway inflammation and mucus hypersecretion. Although distinct in origin, these conditions often coexist in COPD patients and together contribute to airflow limitation.
Q4: Why is alpha-1 antitrypsin deficiency a genetic risk factor for COPD?
Alpha-1 antitrypsin is a protective enzyme that counteracts proteolytic enzymes in the lungs. Deficiency of this protein impairs the lungs' ability to defend against tissue-damaging enzymes, leading to accelerated lung damage and increased risk of early-onset emphysema even with minimal environmental exposure.
Q5: How do occupational and environmental exposures contribute to COPD development?
Long-term occupational exposure to dust such as silica and cotton, and chemical fumes, damages lung tissue over time. Indoor air pollution from biomass fuels in poorly ventilated homes and urban air pollution also increase COPD risk. These exposures accumulate gradually, leading to progressive lung damage and airflow limitation.
Q6: What role do early-life factors play in COPD susceptibility?
Early-life factors including recurrent respiratory infections, poor lung development from prematurity, and childhood asthma increase susceptibility to COPD later in life. These conditions may compromise initial lung development and function, making individuals more vulnerable to subsequent environmental exposures and chronic inflammation.
Q7: Is COPD preventable and treatable?
Yes, COPD is preventable and treatable. It is a common lung disorder characterized by persistent respiratory symptoms and airflow limitation. Prevention focuses on avoiding harmful exposures like tobacco smoke and occupational hazards, while treatment aims to manage symptoms and slow disease progression.